Literature DB >> 28184947

[Neuroendocrine tumor therapy (NETTER-1) trial: 177Lu-DOTA-TATE for neuroendocrine tumors].

T Derlin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28184947     DOI： 10.1007/s00117-017-0221-3

Source DB:  PubMed          Journal:  Radiologe        ISSN： 0033-832X            Impact factor:   0.635


× No keyword cloud information.
  5 in total

Review 1.  Carcinoid tumors.

Authors:  M H Kulke; R J Mayer
Journal:  N Engl J Med       Date:  1999-03-18       Impact factor: 91.245

2.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

3.  Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history.

Authors:  E P Krenning; P P Kooij; W H Bakker; W A Breeman; P T Postema; D J Kwekkeboom; H Y Oei; M de Jong; T J Visser; A E Reijs
Journal:  Ann N Y Acad Sci       Date:  1994-09-15       Impact factor: 5.691

4.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

5.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Authors:  Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.